ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for allegedly inflating its 2025 revenue growth through channel stuffing, a practice where excess product is pushed to distributors to boost sales figures artificially. Culper Research reported that ADMA's actual revenue likely declined by 3% in 2025, contrary to the reported 20% growth, causing the stock price to drop 29% in two days. Investors who suffered losses may have legal options and are encouraged to contact the law firm for potential class action participation.
A class action lawsuit has been filed against ADMA Biologics, alleging the company failed to disclose an undisclosed related party transaction, engaged in channel stuffing to inflate revenue, and lacked proper internal controls. The lawsuit covers se...
A shareholder class action lawsuit has been filed against ADMA Biologics, alleging the company made false and misleading statements and failed to disclose key adverse facts. The claims include undisclosed related party transactions, channel stuffing ...
ADMA Biologics and some executives face a securities fraud lawsuit alleging they misled investors by inflating revenue through excess shipments of their product ASCENIV and hiding a related-party distribution deal. The truth surfaced after a report i...
